AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 135 filers reported holding AMYLYX PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $84,427 | -96.2% | 4,611 | -95.5% | 0.00% | -100.0% |
| Q2 2023 | $2,199,601 | -42.4% | 101,975 | -21.6% | 0.00% | 0.0% |
| Q1 2023 | $3,815,755 | +229.1% | 130,053 | +314.5% | 0.00% | – |
| Q4 2022 | $1,159,380 | -69.3% | 31,377 | -76.6% | 0.00% | -100.0% |
| Q3 2022 | $3,772,000 | +125633.3% | 133,987 | +75598.9% | 0.00% | – |
| Q2 2022 | $3,000 | -94.3% | 177 | -95.7% | 0.00% | – |
| Q1 2022 | $53,000 | – | 4,157 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alpha Wave Global, LP | 853,262 | $18,404,861 | 12.06% |
| Stonepine Capital Management, LLC | 1,121,028 | $24,180,574 | 8.72% |
| GREAT POINT PARTNERS LLC | 968,795 | $20,896,908 | 4.09% |
| Ghost Tree Capital, LLC | 550,000 | $11,863,500 | 3.92% |
| Perceptive Advisors | 4,873,919 | $105,130,433 | 3.04% |
| Altium Capital Management LP | 185,000 | $3,990,450 | 3.02% |
| Boxer Capital, LLC | 2,084,000 | $44,952 | 2.08% |
| SECTORAL ASSET MANAGEMENT INC | 387,310 | $8,354,277 | 1.39% |
| AlphaCentric Advisors LLC | 108,000 | $2,329,560 | 1.29% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 680,035 | $14,668,355 | 0.80% |